Relapsed/refractory non-Hodgkin's lymphoma. Other and unspecified types of non-Hodgkin lymphoma
Conditions
Interventions
Intervention 1: Intervention group: Patients with relapsed/refractory non-Hodgkin's lymphomas referred to Taleghani Hospital. 6 patients in the intervention group receiving combination therapy with ri
Sponsors
Shahid Beheshti University of Medical Sciences
Eligibility
Sex/Gender
All
Age
12 Years to 80 Years
Inclusion criteria
Inclusion criteria: Patients with non-Hodgkin's lymphomas with the origin of B lymphocytes confirmed based on WHO criteria and clinical and paraclinical evidence Patients with non-response or insufficient response to the first stage of treatment based on clinical and paraclinical evidence Patients with disease recurrence Patients with ECOG index of 0-2
Exclusion criteria
Exclusion criteria: Non-Hodgkin's B-cell lymphomas Patients with clinical and paraclinical full recovery Non-Hodgkin's B-cell lymphomas Patients with clinical and paraclinical appropriate response to the first stage of treatment
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The adverse effects during or after combination therapy with allogeneic NK cells and rituximab. Timepoint: From the first dose of NK cells infusion until six months after its last dose. Method of measurement: The patient's statements and the medical team's examinations during the patient's regular visits to the bone marrow transplantation clinic for follow-up.;Response to treatment (Based on hematologic, morphologic and molecular assessments). Timepoint: From the first dose of NK cells infusion until six months after its last dose. Method of measurement: Regular patient examination in bone marrow transplantation clinic for follow-up. | — |
Secondary
| Measure | Time frame |
|---|---|
| Event Free Survival. Timepoint: From the first dose of NK cells infusion until six months after its last dose. Method of measurement: Regular patient visits to bone marrow transplantation clinic for follow-up and regular telephone monitoring of patients.;Progression free survival. Timepoint: From the first dose of NK cells infusion until six months after its last dose. Method of measurement: Regular patient visits to bone marrow transplantation clinic for follow-up and regular telephone monitoring of patients.;Non-relapse mortality. Timepoint: From the first dose of NK cells infusion until six months after its last dose. Method of measurement: Regular patient visits to bone marrow transplantation clinic for follow-up and regular telephone monitoring of patients.;Overall survival. Timepoint: From the first dose of NK cells infusion until six months after its last dose. Method of measurement: Regular patient visits to bone marrow transplantation clinic for follow-up and regular telephone monitoring of patients. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactElham Roshandel
Shahid Beheshti University of Medical Sciences
Outcome results
None listed